Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis drug, zanzalintinib, in ...

Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar ...

A gene therapy for hearing loss, an experimental pancreatic cancer treatment and seven other medications have been chosen as the first recipients of a new voucher the Food and Drug Administration is ...

I-Mab is rebranding as a company that will form individual drugmaking subsidiaries. Elsewhere, Sanofi cut an immune drug deal and investors poured $140 million into a new hair loss treatment.

Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive ...

The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to ...

The findings position Fabhalta to secure a standard approval in IgA nephropathy — a crowded area of drug research — at a time ...

The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...

Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to ...

Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where ...

The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer ...